Brokerages Set Cardlytics, Inc. (NASDAQ:CDLX) Price Target at $6.92

Shares of Cardlytics, Inc. (NASDAQ:CDLX) have earned an average rating of “Hold” from the seven analysts that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $6.92.

A number of equities research analysts have commented on CDLX shares. Needham & Company LLC restated a “hold” rating on shares of Cardlytics in a research report on Thursday, November 7th. Craig Hallum upgraded Cardlytics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. Finally, Evercore ISI started coverage on Cardlytics in a research report on Friday, October 11th. They set an “in-line” rating and a $4.00 price objective for the company.

Insiders Place Their Bets

In other Cardlytics news, CFO Alexis Desieno sold 25,118 shares of Cardlytics stock in a transaction on Friday, November 15th. The stock was sold at an average price of $3.43, for a total value of $86,154.74. Following the completion of the transaction, the chief financial officer now owns 116,481 shares in the company, valued at approximately $399,529.83. The trade was a 17.74 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Amit Gupta sold 22,607 shares of the stock in a transaction on Thursday, October 24th. The stock was sold at an average price of $3.85, for a total value of $87,036.95. Following the sale, the chief executive officer now owns 178,519 shares in the company, valued at $687,298.15. The trade was a 11.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 69,007 shares of company stock worth $251,297 over the last three months. 4.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Cardlytics

Several hedge funds and other institutional investors have recently made changes to their positions in CDLX. Geode Capital Management LLC boosted its stake in shares of Cardlytics by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company’s stock valued at $3,371,000 after purchasing an additional 73,484 shares during the last quarter. Marshall Wace LLP raised its position in shares of Cardlytics by 6.8% during the 2nd quarter. Marshall Wace LLP now owns 814,281 shares of the company’s stock valued at $6,685,000 after acquiring an additional 52,081 shares during the last quarter. RBF Capital LLC lifted its stake in shares of Cardlytics by 311.9% in the 3rd quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock valued at $1,562,000 after purchasing an additional 369,620 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Cardlytics by 3.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,343 shares of the company’s stock worth $1,249,000 after purchasing an additional 11,388 shares during the last quarter. Finally, GSA Capital Partners LLP boosted its position in shares of Cardlytics by 1,273.2% in the 3rd quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock worth $1,223,000 after purchasing an additional 354,474 shares during the last quarter. 68.10% of the stock is owned by institutional investors and hedge funds.

Cardlytics Trading Down 1.4 %

Shares of NASDAQ:CDLX opened at $3.44 on Friday. The company has a 50 day moving average of $3.90 and a 200-day moving average of $4.78. The firm has a market cap of $174.83 million, a P/E ratio of -0.56 and a beta of 1.53. Cardlytics has a twelve month low of $2.89 and a twelve month high of $20.52. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40.

Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.18. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The firm had revenue of $67.06 million for the quarter, compared to analysts’ expectations of $57.77 million. During the same quarter last year, the business posted ($0.26) EPS. Cardlytics’s revenue was down 15.1% on a year-over-year basis. As a group, analysts anticipate that Cardlytics will post -1.52 earnings per share for the current fiscal year.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.